Compare EUDA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | ICCC |
|---|---|---|
| Founded | 2021 | 1982 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 55.5M |
| IPO Year | N/A | 1995 |
| Metric | EUDA | ICCC |
|---|---|---|
| Price | $0.82 | $6.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 72.0K | 12.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.33 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | $137.25 | N/A |
| Revenue Next Year | $361.43 | N/A |
| P/E Ratio | $123.62 | ★ $32.67 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $0.71 | $4.32 |
| 52 Week High | $4.30 | $7.60 |
| Indicator | EUDA | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 47.40 |
| Support Level | $0.71 | $6.12 |
| Resistance Level | $3.31 | $6.91 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 21.60 | 20.00 |
EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.